Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that combining D-004 with finasteride results in more significant prevention of testosterone-induced prostate enlargement in rats compared to using either treatment alone.

Certain gene variants may raise the risk of prostate enlargement, but taking NSAIDs could reduce this risk.

This study concluded that five-alpha-reductase inhibitors may reduce prostate cancer risk but could increase the risk of high-grade prostate cancer in men regularly screened for the disease.

In this study, low dose finasteride or dutasteride treatment was found to reduce prostate specific antigen levels in men with androgenetic alopecia, though levels sometimes remained stable or increased in those with low baseline PSA.

Higher CRP levels suggest chronic inflammation is linked to bladder-related urinary symptoms in men with enlarged prostates.

Finasteride treats enlarged prostate and baldness, but may cause limited urinary improvement and sex-related side effects.

In this study, 5 mg of finasteride per day significantly improved urinary symptoms and reduced prostate volume in men with benign prostatic hyperplasia, but increased the risk of sexual dysfunction.

This study found that combining 5-alpha reductase inhibitors with alpha-blockers provided the best symptomatic relief and reduced the risk of clinical progression for BPH, while PDE5 inhibitors could offset sexual side effects.

This study found that an alcoholic extract of Glycyrrhiza glabra significantly reduced prostate weight and serum testosterone in castrated rats given testosterone, indicating potential antiandrogenic properties.

This review summarizes recent research and patents on 17β-HSD3, 17β-HSD5, and 3α-HSD3 inhibitors, suggesting their potential in treating androgen-dependent diseases, but reports no new clinical results.

Taking dutasteride every other day works as well as daily and better preserves sexual function.

This study found that overexpression of the enzyme SSAT in a mouse model significantly reduced prostate tumor size and progression, suggesting it could be a promising strategy against prostate cancer.

In this study, men with benign prostatic hyperplasia who took finasteride for four years experienced reduced urinary symptoms, fewer surgeries, less acute urinary retention, increased urinary flow rates, and decreased prostate volume.

This review summarizes NCCN guidelines for prostate cancer early detection, focusing on strategies to maximize detection of potentially curable cases while minimizing unnecessary procedures, but it reports no new clinical findings.

The study found that ezetimibe effectively reduced prostate enlargement in an animal model of benign prostatic hyperplasia, suggesting it as a potential alternative or complementary treatment.

This article reviews the mechanism, use, and alternatives for finasteride in dermatology and provides no new clinical results.

This study found that a 3 mm margin around the prostate CTV may be adequate if accompanied by frequent imaging, but superior-inferior displacements were notably greater than in other directions.

This review examines the role of steroidal inhibitors in treating prostatic diseases but presents no new clinical results.

This article reviews the Clinical Pearls presentation format introduced at the American College of Physicians' 2001 meeting for its effectiveness in applying practical clinical tips, but provides no new empirical results.

This study modeled how differences in trial settings and protocols, such as biopsy compliance and control arm screening, can explain the varying prostate cancer mortality reductions observed in the ERSPC and PLCO trials.

In this study, FCE 28260 showed greater potency than finasteride in inhibiting 5α-reductase enzymes and reducing prostate DHT levels in rats.

This review discusses the effects of 5ARI drugs on male reproductive parameters, reporting potential decreases in sperm count and motility more significantly in men with pre-existing oligozoospermia, but does not provide fertility outcomes.

In this study, short-term treatment with lovastatin showed no effect on symptom severity, prostate volume, or PSA levels in men with prostatic enlargement from presumed benign prostatic hyperplasia.

In this experimental study on Holtzman rats with induced benign prostatic hyperplasia, the researchers observed that the extract of Physalis peruviana (aguaymanto) had a greater therapeutic effect on prostate weight reduction and prostatic epithelium height compared to finasteride and terazosine.

In this rat study, finasteride treatment significantly reduced body, testis, epididymis, and prostate weights and affected testicular histology, indicating potential negative impacts on testicular function.

This study concludes that the accuracy of PSA testing for prostate cancer diagnosis is not only maintained but may be increased when used alongside 5-alpha reductase inhibitors like finasteride and dutasteride.

After the FDA's 2011 warning about a potential prostate cancer risk with 5-alpha reductase inhibitors, this study observed a significant decrease in their prescriptions, notably a 49% drop among men with benign prostatic hyperplasia, while primary care providers reduced prescriptions by 60%.

This article discusses the approval and perceived potential of Provenge, a new prostate cancer vaccine, highlighting its capability to extend survival in certain patients while also noting ongoing debates about its cost and mechanisms; it reports no new clinical results.

This study introduced a new spectrofluorometric method using a synthesized organic fluorophore to effectively analyze darolutamide and thalidomide in pharmaceutical preparations and biofluids.

Among a Han Chinese cohort, this study found that a higher genetic risk score was linked to increased susceptibility to BPH, larger prostate size, reduced effectiveness of 5ARI treatment, and a higher risk of undergoing TURP.